Prestige Consumer Healthcare Inc. (PBH): Cost of Revenue
$493.13M
Year ended 2026-03-31
$513.45M
Trailing 12 months to 2026-06-30
-0.6%
3-year compound annual growth
+4.5%
5-year compound annual growth
+3.8%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $493.13M | -2.0% | 2026-05-14, From 2025-04-01 |
| 2025-03-31 | $503.30M | +0.5% | 2026-05-14, From 2024-04-01 |
| 2024-03-31 | $500.91M | -0.3% | 2026-05-14, From 2023-04-01 |
| 2023-03-31 | $502.43M | +7.8% | 2025-05-09, From 2022-04-01 |
| 2022-03-31 | $466.17M | +17.8% | 2024-05-15, From 2021-04-01 |
| 2021-03-31 | $395.89M | -3.6% | 2023-05-05, From 2020-04-01 |
| 2020-03-31 | $410.79M | -2.2% | 2022-05-06, From 2019-04-01 |
| 2019-03-31 | $420.20M | -9.6% | 2021-05-07, From 2018-04-01 |
| 2018-03-31 | $464.67M | +21.7% | 2020-05-08, From 2017-04-01 |
| 2017-03-31 | $381.77M | +12.6% | 2019-05-13, From 2016-04-01 |
| 2016-03-31 | $339.04M | n/a | 2018-05-10, From 2015-04-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $493.13M | -2.0% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $89.00M | +8.7% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2024-12-31 | $6.23M | n/a |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $246.00M | +6.5% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
| Alkermes plc. (ALKS) | 2025-12-31 | $196.46M | -19.9% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.01B | +12.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
Compare PBH, ACAD, MDGL, INDV side by side · Screen every company in Pharmaceutical Preparations ↗